Loading
microcirculation using the video microscopy tool. / Cardiogenic Shock · Interventional Study
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a recruiting pilot ancillary study nested within the EMPASHOCK trial, designed to measure real-time microcirculatory changes in cardiogenic shock patients treated with empagliflozin versus control, using video microscopy at 48 hours post-randomization. No results are yet available in this registry record; the study explores a mechanistic hypothesis about empagliflozin's vasculo-protective endothelial effects on systemic microcirculation, a parameter the brief summary suggests may predict outcomes better than macrocirculatory measures.
Interventional, Randomized, Parallel, Single masking, Screening purpose. Cardiogenic Shock; age from 18 Years. Intervention: Patient in cardiogenic shock under empagliflozin. Compared with: Patient in cardiogenic shock without empagliflozin — Sham Comparator. n = 24. 1 site: France.
This is a recruiting pilot ancillary study nested within the EMPASHOCK trial, designed to measure real-time microcirculatory changes in cardiogenic shock patients treated with empagliflozin versus control, using video microscopy at 48 hours post-randomization. No results are yet available in this registry record; the study explores a mechanistic hypothesis about empagliflozin's vasculo-protective endothelial effects on systemic microcirculation, a parameter the brief summary suggests may predict outcomes better than macrocirculatory measures.
Primary outcome is a microcirculatory imaging parameter, not a clinical hard endpoint (mortality, rehospitalization, or organ failure).
If positive, findings would provide mechanistic evidence that empagliflozin's benefit in acute heart failure and cardiogenic shock involves preserved or improved microcirculation. However, this is a pilot study with a surrogate endpoint; clinical hard outcome data would be required to change practice.
This is a recruiting pilot study with no results posted; it aims to explore a mechanistic hypothesis about empagliflozin's microcirculatory effects in cardiogenic shock using a surrogate imaging endpoint.
As stated by the source record.
Quoted from the source exactly as published.
If positive, findings would provide mechanistic evidence that empagliflozin's benefit in acute heart failure and cardiogenic shock involves preserved or improved microcirculation. However, this is a pilot study with a surrogate endpoint; clinical hard outcome data would be required to change practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07141355). This is a study registration, not published results. Lead sponsor: University Hospital, Strasbourg, France. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 24 participants (ESTIMATED). Conditions: Cardiogenic Shock. Interventions: DIAGNOSTIC_TEST: microcirculation using the video microscopy tool.. Primary outcome measures: The difference in the evolution of a parameter reflecting the microcirculation between the two groups at 48 hours post-randomization. , Comparison between Day 0 and 48 hours. Brief summary: Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%. The EMPULSE-HF trial showed that early introduction of empagliflozin in stabilized patients with acute heart failure led to a composite benefit in mortality, rehospitalization, and quality of life. Growing evidence suggests that cardiogenic shock isn't just a problem of systemic macrocirculation (blood pressure, cardiac output). It also involves significant abnormalities in the systemic microcirculation. In fact, these microcirculatory parameters have proven to be better predictors of patient outcomes than traditional macrocirculatory measures. Given its known vasculo-protective effects on the endothelium, empagliflozin may have a beneficial impact on the microcirculation, potentially explaining its positive effects in cardiogenic shock. This study will explore this hypothesis by analyzing the microcirculation in real-time using the CytoCam-IDF imaging videomicroscope and its MicroTools software. The goal is to gain a deeper understanding of how empagliflozin affects the microcirculation during cardiogenic shock.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.